| Symbol | TIL |
|---|---|
| Name | INSTIL BIO, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 3963 MAPLE AVENUE,SUITE 350, DALLAS, Texas, 75219, United States |
| Telephone | +1 972 499-3350 |
| Fax | — |
| — | |
| Website | https://www.instilbio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001789769 |
| Description | Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using our Co-Stimulatory Antigen Receptor, or CoStAR, platform. The companys lead product candidate, ITIL-168, is an autologous TIL therapy that it is initially developing for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma. Additional info from NASDAQ: |
Director McGaughy R Kent Jr 🟢 acquired 6.5K shares (1 derivative) of Instil Bio, Inc. (TIL) at $7.93 Transaction Date: Jun 11, 2026 | Filing ID: 000003
Read moreDirector Matcham George 🟢 acquired 6.5K shares (1 derivative) of Instil Bio, Inc. (TIL) at $7.93 Transaction Date: Jun 11, 2026 | Filing ID: 000002
Read moreDirector Gibson Neil W 🟢 acquired 6.5K shares (1 derivative) of Instil Bio, Inc. (TIL) at $7.93 Transaction Date: Jun 11, 2026 | Filing ID: 000002
Read moreDirector Binder Gwendolyn 🟢 acquired 6.5K shares (1 derivative) of Instil Bio, Inc. (TIL) at $7.93 Transaction Date: Jun 11, 2026 | Filing ID: 000002
Read moreInstil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Read moreNew Form DEFA14A - Instil Bio, Inc. <b>Filed:</b> 2026-04-24 <b>AccNo:</b> 0001789769-26-000032 <b>Size:</b> 506 KB
Read moreInstil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Read more